Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer - Top-Institutions - MDSpire

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

  • By

  • Yu Xia

  • Jiawei Song

  • Haiyan Zhang

  • Shiwei Liu

  • Jing Luo

  • July 17, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Cancer and Leukemia Group B
    Cancer and Leukemia Group B

    Chicago, Illinois

    Key Differentiators

    • Oncology

  • #5

    Baylor College of Medicine
    Baylor College of Medicine

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

  • by Yu Xia, Jiawei Song, Haiyan Zhang, Shiwei Liu, Jing Luo

  • July 17, 2026

Related Content

Machine learning-based prognostic model for triple-negative breast cancer with axillary lymph node metastasis

Multi-scale information bottleneck with confidence-weighted decision fusion for robust breast ultrasound lesion classification

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study